HUTCHMED (NASDAQ:HCM) Lowered to Buy Rating by Wall Street Zen

Wall Street Zen cut shares of HUTCHMED (NASDAQ:HCMFree Report) from a strong-buy rating to a buy rating in a report issued on Saturday.

Separately, HSBC lowered HUTCHMED from a “buy” rating to a “hold” rating in a report on Tuesday, May 13th.

Read Our Latest Analysis on HCM

HUTCHMED Stock Down 4.6%

Shares of HUTCHMED stock opened at $16.90 on Friday. The company has a 50-day simple moving average of $14.35 and a two-hundred day simple moving average of $14.75. HUTCHMED has a 52-week low of $11.51 and a 52-week high of $21.50. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.

Institutional Investors Weigh In On HUTCHMED

Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC grew its position in HUTCHMED by 128.0% during the first quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after buying an additional 124,771 shares during the period. Goldman Sachs Group Inc. grew its holdings in HUTCHMED by 8.5% during the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock valued at $1,413,000 after purchasing an additional 7,342 shares during the period. Vident Advisory LLC grew its holdings in HUTCHMED by 78.3% during the first quarter. Vident Advisory LLC now owns 19,728 shares of the company’s stock valued at $297,000 after purchasing an additional 8,664 shares during the period. XY Capital Ltd raised its stake in shares of HUTCHMED by 142.4% in the first quarter. XY Capital Ltd now owns 113,136 shares of the company’s stock worth $1,702,000 after buying an additional 66,460 shares during the period. Finally, Crossmark Global Holdings Inc. raised its stake in shares of HUTCHMED by 31.4% in the first quarter. Crossmark Global Holdings Inc. now owns 24,420 shares of the company’s stock worth $367,000 after buying an additional 5,829 shares during the period. 8.82% of the stock is currently owned by hedge funds and other institutional investors.

About HUTCHMED

(Get Free Report)

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

Featured Articles

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.